Dec 31, 2025 • The Globe and Mail
SOMEWHAT-BULLISH
How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?
Boston Scientific's Cardiovascular segment, operating in a $50 billion market, anticipates nearly 9% growth through its long-range plan, driven by strong performance in Electrophysiology and Interventional Cardiology Therapies. The company expects to outpace overall market growth, with key products like WATCHMAN serving as significant growth engines, bolstered by positive clinical trial outcomes. While also highlighting recent developments from peers Medtronic and Johnson & Johnson, the article notes Boston Scientific's stock performance and a "Buy" rating from Zacks.
Dec 31, 2025 • openPR.com
SOMEWHAT-BULLISH
Disposable Insulin Pumps Market is expected to reach US$ 6.9 billion by 2032 | Major Companies - Medtronic, Roche, Animas Corporation, Tandem Diabetes Care.
The Global Disposable Insulin Pumps Market is projected to grow from US$ 3.83 billion in 2024 to US$ 6.9 billion by 2032, exhibiting a CAGR of 7.76%. This growth is driven by recent innovations and increasing adoption of tubeless patch pumps for diabetes management in regions like the US and Europe. Key players in this market include Medtronic, Insulet Corporation, and Roche.
Dec 30, 2025 • Yahoo Finance
BULLISH
Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical
Zacks Equity Research highlights Veracyte (VCYT), IDEXX Laboratories (IDXX), and Intuitive Surgical (ISRG) as key players in the Medical Instruments industry. Despite macroeconomic headwinds and regulatory adjustments, these companies have adapted well, leveraging generative AI and M&A trends. The industry outlook, however, remains subdued according to the Zacks Industry Rank, even as the global AI in healthcare market projects significant growth.
Dec 30, 2025 • Finviz
SOMEWHAT-BULLISH
Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment
Abbott Laboratories (ABT) has received FDA approval for its Volt™ PFA System, designed to treat patients with atrial fibrillation (AFib). This system will soon be commercially available in the U.S. and is already expanding in the EU after CE Mark approval. The approval follows the VOLT-AF IDE study, which demonstrated the system's safety and effectiveness for both paroxysmal and persistent AFib.
Dec 30, 2025 • The Globe and Mail
SOMEWHAT-BULLISH
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?
This article compares two medical device giants, Boston Scientific (BSX) and Resmed (RMD), evaluating their market positions, growth strategies, and financial outlook. While both companies show promising prospects and strong analyst ratings, Boston Scientific is highlighted as a more attractive option due to its current price performance and diversified growth streams, carrying a Zacks Rank #2 (Buy) compared to Resmed's #3 (Hold). The article details each company's recent achievements, product innovations, and market expansion efforts.
Dec 30, 2025 • openPR.com
BULLISH
Bioelectric Medicine Market is Thriving Worldwide | Medtronic
The global bioelectric medicine market, valued at USD 23.27 billion in 2025, is projected to reach USD 43.09 billion by 2032, exhibiting a CAGR of 9.2%. This growth is driven by increasing industry demand, expanding applications, and technological advancements. The report provides a comprehensive analysis of market drivers, restraints, opportunities, and competitive landscapes, featuring key companies like Medtronic plc. and Boston Scientific Corporation.